Q1 Earnings Forecast for OKYO Pharma Issued By HC Wainwright

OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) – Equities research analysts at HC Wainwright raised their Q1 2026 earnings per share estimates for OKYO Pharma in a note issued to investors on Tuesday, September 23rd. HC Wainwright analyst Y. Chen now expects that the company will post earnings per share of ($0.02) for the quarter, up from their previous estimate of ($0.04). HC Wainwright has a “Buy” rating and a $7.00 price target on the stock. The consensus estimate for OKYO Pharma’s current full-year earnings is ($0.17) per share. HC Wainwright also issued estimates for OKYO Pharma’s Q2 2026 earnings at ($0.02) EPS, Q3 2026 earnings at ($0.05) EPS, Q4 2026 earnings at ($0.08) EPS and FY2026 earnings at ($0.19) EPS.

OKYO has been the subject of several other research reports. Zacks Research raised OKYO Pharma to a “hold” rating in a research note on Tuesday, September 16th. Wall Street Zen upgraded OKYO Pharma to a “hold” rating in a report on Saturday, August 9th. One analyst has rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $7.00.

OKYO Pharma Stock Up 5.2%

Shares of OKYO stock opened at $2.22 on Thursday. The business has a 50-day moving average price of $2.51 and a two-hundred day moving average price of $2.04. OKYO Pharma has a 12-month low of $0.90 and a 12-month high of $3.35.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Wealth Enhancement Advisory Services LLC purchased a new position in shares of OKYO Pharma during the 2nd quarter worth approximately $28,000. Dauntless Investment Group LLC bought a new stake in shares of OKYO Pharma in the 1st quarter worth approximately $2,526,000. Finally, FNY Investment Advisers LLC bought a new stake in shares of OKYO Pharma in the 1st quarter worth approximately $25,000. Hedge funds and other institutional investors own 2.97% of the company’s stock.

About OKYO Pharma

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease.